Obstetrical Complications
2
Pipeline Programs
2
Companies
3
Clinical Trials
1 recruiting
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
2
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
2 companies ranked by most advanced pipeline stage
Human BioSciencesWV - Martinsburg
2 programs2
Azithromycin InjectionPhase 31 trial
Tranexamic AcidPhase 31 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
2027
Human BioSciencesAzithromycin Injection
Human BioSciencesTranexamic Acid
BioserenityTOCONAUTE
Clinical Trials (3)
Total enrollment: 19,060 patients across 3 trials
Azithromycin Prophylaxis for PRElabor CEsarean DElivery Trial
Start: Nov 2024Est. completion: Nov 20278,000 patients
Phase 3Recruiting
Tranexamic Acid for the Prevention of Obstetrical Hemorrhage After Cesarean
Start: Mar 2018Est. completion: Oct 202111,000 patients
Phase 3Completed
Maternal-Fetal Monitoring by Connected Abdominal Patch - MOMA
Start: Aug 2022Est. completion: Nov 202360 patients
N/ACompleted
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
2 late-stage (Phase 3) programs, potential near-term approvals
1 actively recruiting trials targeting 19,060 patients
2 companies competing in this space
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.